This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
== Board of directors == The board of directors is composed of thirteen members, in office until the approval of the financial statements at 31 December 2020, with Alberto Vacchi in the role of chairman and executive CEO. Marco Vacchi is the honorary president.
Diabetes mellitus type 1 is a chronic autoimmune disease in which the immune system attacks the insulin-secreting beta cells of the pancreas. Insulin is needed to keep blood sugar levels within optimal ranges, and its lack can lead to high blood sugar. As an untreated chronic condition, complications including accelerated vascular disease, diabetic retinopathy, kidney disease and neuropathy can result. In addition, if there is not enough insulin for glucose to be used within cells, the medical emergency diabetic ketoacidosis, which is often the first symptom that a person with type 1 diabetes may have, can result. Type 1 diabetes can develop at any age but is most often diagnosed before age 40. For people living with type 1 diabetes, insulin injections are critical for survival. An experimental procedure to treat type 1 diabetes is pancreas transplantation or isolated transplantation of islet cells to supply a person with functioning beta cells.
== Season 1 (2015) == Seven bakers and chefs competed in a four-episode baking tournament. One person got eliminated every week until the final episode where one person was eliminated early on and the final three compete for the grand prize of $25,000. Judges for this season are Carla Hall, Ron Ben-Israel, and Sherry Yard.
Sources: en.wikipedia.org
Malnutrition-related diabetes mellitus (MRDM), also known as Type 5 diabetes and formerly as Type J diabetes, is a type of diabetes mellitus characterized by reduced insulin production (similar to Type 1 diabetes). However, in MRDM, the insulin deficiency is primarily linked to childhood malnutrition rather than autoimmune damage to the pancreatic beta cells. Unlike Type 1 diabetes, patients with Type 5 diabetes do not develop ketonuria or ketosis.
In Normandy, the 82nd gained its first Medal of Honor of the war, belonging to Private first class Charles N. DeGlopper of the 325th GIR. When the division was relieved in early July, the 82nd had seen a month straight of severe combat. Casualties were heavy. Losses included 5,245 troopers killed, wounded, or missing- a 46% casualty rate. Major General Ridgway's post-battle report stated in part, "... 33 days of action without relief, without replacements. Every mission accomplished. No ground gained was ever relinquished." Following Normandy, the 82nd Airborne Division returned to England to rest and refit for future airborne operations. The 82nd became part of the newly organized XVIII Airborne Corps, which consisted of the 17th, 82nd, and 101st Airborne Divisions. Ridgway was given command of the corps but was not officially promoted to lieutenant general until 1945. His recommendation for succession as division commander was Brigadier General James M. Gavin, previously the 82nd's assistant division commander. Upon being promoted to major general in October 1944 at the age of 37, Gavin became the youngest general since the Civil War to command a US Army division.
The chestnut or sorrel color, genetically considered "red", is caused by one of two recessive alleles at the extension locus (genetics). Extension has three known alleles: the wildtype "E", necessary for the bay and black coat colors, plus two mutations "e" and "ea", both of which are capable of causing the chestnut color. Each individual horse has two copies of the extension gene. If either copy is "E", then the horse will be bay- or black-based. But if the two copies are any combination of "e" and "ea" (e/e, e/ea, or ea/ea), then the horse will be red-based. Alternate extension "ea" is rare and there is no known difference in appearance between it and the more common "e". Because the red color is recessive, two bay or black parents can produce a chestnut foal if both carry "e" or "ea". However, two chestnut parents cannot produce a bay or black foal. The extension locus (genetics) is found on chromosome 3 (ECA3) and is part of the gene that codes for the equine melanocortin 1 receptor (MC1R). This receptor is part of a signalling pathway which when activated causes melanocytes to produce eumelanin, or black pigment, instead of pheomelanin, or red pigment. The two mutant alleles "e" and "ea" code for dysfunctional receptors unable to activate this pathway, so absent "E", only red pigment can be produced. At least one copy of the functional "E" allele is required to activate the signal and produce black pigment.
Sources: en.wikipedia.org
Early placenta insulin-like peptide is a protein that in humans is encoded by the INSL4 gene. INSL4 encodes the insulin-like 4 protein, a member of the insulin superfamily. INSL4 encodes a precursor that undergoes post-translational cleavage to produce 3 polypeptide chains, A-C, that form tertiary structures composed of either all three chains, or just the A and B chains. Expression of INSL4 products occurs within the early placental cytotrophoblast and syncytiotrophoblast.
Only two divisions (43rd and 53rd), two armoured brigades, and a parachute brigade were to remain allocated for NATO and the defence of Western Europe; the other eight divisions were placed on a lower establishment for home defence only. The territorial units of the Royal Armoured Corps were also reduced in number to nine armoured regiments and eleven reconnaissance regiments. This was effected by the amalgamation of pairs of regiments, and the conversion of four RAC units to an infantry role. The new parachute brigade group become the 44th Independent Parachute Brigade Group. British forces contracted dramatically as the end of conscription in 1960 came in sight as announced in the 1957 Defence White Paper. On 20 July 1960, a reorganisation of the TA was announced in the House of Commons. The territorials were to be reduced from 266 fighting units to 195. There was to be a reduction of 46 regiments of the Royal Artillery, 18 battalions of infantry, 12 regiments of the Royal Engineers and two regiments of the Royal Corps of Signals. The reductions were carried out in 1961, mainly by amalgamating units. Thus, on 1 May 1961, the TA divisional headquarters were merged with regular army districts, which were matched with Civil Defence Regions to aid mobilisation for war. The Army Reserve Act of April 1962 made provision for a new TA Emergency Reserve (TAER), within existing TA units, who could be called out without Royal Proclamation as individuals to reinforce regular units around the world, for up to six months in every twelve.
=== Galactosemia === Galactosemia results from an inability to process galactose, a simple sugar. This deficiency occurs when the gene for galactose-1-phosphate uridylyltransferase (GALT) has any number of mutations, leading to a deficiency in the amount of GALT produced. There are two forms of Galactosemia: classic and Duarte. Duarte galactosemia is generally less severe than classic galactosemia and is caused by a deficiency of galactokinase. Galactosemia renders infants unable to process the sugars in breast milk, which leads to vomiting and anorexia within days of birth. Most symptoms of the disease are caused by a buildup of galactose-1-phosphate in the body. Common symptoms include liver failure, sepsis, failure to grow, and mental impairment, among others. Buildup of a second toxic substance, galactitol, occurs in the lenses of the eyes, causing cataracts. Currently, the only available treatment is early diagnosis followed by adherence to a diet devoid of lactose, and prescription of antibiotics for infections that may develop.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.